5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.41▼ | 2.44▼ | 2.44▼ | 2.44▼ | 2.53▼ |
MA10 | 2.47▼ | 2.47▼ | 2.47▼ | 2.50▼ | 2.42▼ |
MA20 | 2.47▼ | 2.48▼ | 2.49▼ | 2.50▼ | 2.61▼ |
MA50 | 2.47▼ | 2.49▼ | 2.48▼ | 2.35▲ | N/A |
MA100 | 2.47▼ | 2.50▼ | 2.46▼ | 2.67▼ | N/A |
MA200 | 2.48▼ | 2.31▼ | 2.36▼ | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.020▼ | -0.019▼ | -0.020▼ | -0.026▼ | N/A |
RSI | 40.466▼ | 41.214▼ | 41.157▼ | 45.061▼ | 35.994▼ |
STOCH | 46.230 | 54.951 | 54.951 | 27.589 | 64.449 |
WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -77.107▼ | -52.705 |
CCI | -140.440▼ | -147.722▼ | -147.857▼ | -132.673▼ | -19.273 |
Monday, June 02, 2025 01:42 PM
BriaCell Therapeutics Corp. (NASDAQ:BCTX) announced robust overall survival and clinical benefit data from its Bria-IMT and Bria-OTS studies in metastatic breast cancer/MBC at the 2025 ASCO Annual ...
|
Monday, June 02, 2025 04:30 AM
PHILADELPHIA and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq ... and clinical benefit data from its Bria-IMT Phase 2 clinical study, clinical ...
|
Tuesday, May 27, 2025 04:30 AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT), a clinical-stage biotechnology company advancing personalized immunotherapies for cancer, today announced that Bria-OTS has ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 2.30 | 2.537 | 2.20 | 2.357 | 6,100 |
12/06/25 | 2.30 | 2.5475 | 2.25 | 2.4292 | 7,375 |
11/06/25 | 2.5079 | 2.5475 | 2.30 | 2.4121 | 6,160 |
09/06/25 | 2.465 | 2.5299 | 2.45 | 2.4755 | 3,489 |
06/06/25 | 2.60 | 2.60 | 2.32 | 2.548 | 5,400 |
05/06/25 | 2.55 | 2.6772 | 2.40 | 2.42 | 3,602 |
04/06/25 | 2.55 | 2.97 | 2.40 | 2.633 | 6,900 |
03/06/25 | 2.60 | 2.74 | 2.38 | 2.6291 | 13,681 |
02/06/25 | 2.75 | 2.80 | 2.42 | 2.475 | 20,793 |
30/05/25 | 2.55 | 2.641 | 2.30 | 2.64 | 10,400 |
|
|
||||
|
|
||||
|
|